4 papers in the library · 1,105 citations · publishing 2022-2026
Eur Neuropsychopharmacol June 5, 2026 Andreas Reif, A. Elif Anıl Yağcıoğlu, Istvan Bitter et al.
Response to: Commentary on "Long-term treatment with esketamine nasal spray in patients with treatment resistant depression: Results from the ESCAPE-LTE study".
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology June 1, 2026 Andreas Reif, Yağcıoğlu Ae Anıl, Istvan Bitter et al. 3 citations
Optimising patient outcomes in treatment resistant depression (TRD) requires treatments which provide sustained remission, without relapse, and tolerability in the long term. ESCAPE-LTE (NCT04829318) was a phase IV, single-arm, 2-year (104 weeks) long-term extension of ESCAPE-TRD (NCT04338321; 32 weeks), a rater-blinded, randomised, active-controlled trial, which evaluated the safety,...
The British journal of psychiatry : the journal of mental science February 1, 2025 Allan H. Young, Pierre-Michel Llorca, Andrea Fagiolini et al. 7 citations
In patients with treatment resistant depression (TRD), the ESCAPE-TRD study showed esketamine nasal spray was superior to quetiapine extended release. To determine the robustness of the ESCAPE-TRD results and confirm the superiority of esketamine nasal spray over quetiapine extended release. ESCAPE-TRD was a randomised, open-label, rater-blinded, active-controlled phase IIIb trial. Patients had...
The New England journal of medicine November 3, 2022 Guy M. Goodwin, Scott T Aaronson, Oscar Alvarez et al. 1,095 citations
Psilocybin is being studied for use in treatment-resistant depression. In this phase 2 double-blind trial, we randomly assigned adults with treatment-resistant depression to receive a single dose of a proprietary, synthetic formulation of psilocybin at a dose of 25 mg, 10 mg, or 1 mg (control), along with psychological support. The primary end point was the change from baseline to week 3 in the...